The development of Xarelto® (rivaroxaban), a novel oral anticoagulant, has taken another step forward. Phase II results in patients with acute coronary syndrome (ACS) have been chosen for the Late Breaking Clinical Trial session at the American Heart Association's (AHA) upcoming Annual Meeting in New Orleans, USA.

The Abbott Fund joined representatives from the U.S. government, Baylor College of Medicine, the government of Tanzania and other partners today at a U.S. President's Emergency Plan for AIDS Relief (PEPFAR) news conference to announce a joint effort to improve care and treatment for children with HIV/AIDS in Tanzania.

GlaxoSmithKline (GSK) and Valeant Pharmaceuticals International (NYSE: VRX) announced that they have entered into an exclusive worldwide collaboration agreement for the investigational drug retigabine, a first in class neuronal potassium channel opener for treatment of adult epilepsy patients with refractory partial onset seizures.

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc (NYSE: PFE) provided an update on the apixaban clinical development program. The companies announced that new Phase II data in acute coronary syndrome patients (ACS) will be presented at the upcoming meeting of the European Society of Cardiology (ESC).

Lundbeck's partner Teva Pharmaceutical Industries Ltd. has announced that results of the phase III ADAGIO trial were presented during the 12th Congress of European Federation of Neurological Societies (EFNS) in Madrid, Spain. The ADAGIO study showed that Parkinson's disease patients who took Azilect® (rasagiline) 1mg tablets once-daily upon entry into the trial, demonstrated a significant improvement compared to those who initiated therapy with the drug nine months later.

Genzyme Corp. (Nasdaq: GENZ), a global leader in biotechnology, and Medicines for Malaria Venture (MMV), a not-for-profit virtual research and development (R&D) organization dedicated to reducing the burden of malaria, announced a new collaboration with India's Advinus Therapeutics Ltd.

Alpharma, Inc. (NYSE: ALO), a global specialty pharmaceutical company, confirmed that it received an unsolicited, non-binding proposal from King Pharmaceuticals, Inc. (NYSE: KG) to acquire all of the outstanding shares of Alpharma for $33.00 per share in cash. Alpharma said that proposal was identical in all material respects to two prior proposals made privately by King to the company.